Skip to main content
logo
Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
32.21
+0.08 (0.25%)
Aug 18, 2026, 12:32 PM EDT - Market open

Stoke Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
27.59184.4236.568.7812.41-
Revenue Growth
-86.20%404.50%316.34%-29.22%--
Gross Profit
27.59184.4236.568.7812.41-
Operating Income
-223.38-20.59-101.37-114.77-104.36-86.07
Net Income
-207.9-6.89-88.98-104.7-101.07-85.81
Earnings Per Share
-3.33-0.12-1.65-2.38-2.60-2.34
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
354.32390.93246.72201.39229.6219.81
Total Debt
2.684.154.776.845.085.04
Net Cash (Debt)
351.64386.78241.95194.56224.52214.77
Net Cash Growth
0.06%59.86%24.36%-13.34%4.54%-24.95%
Net Cash Per Share
5.636.534.484.425.775.85

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-177.9945.59-86.85-81.07-31.87-66.91
Capital Expenditures
-2.69-0.67-0.2-1.62-3.96-1.2
Free Cash Flow
-180.6844.92-87.05-82.68-35.83-68.11
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-809.69%-11.16%-277.31%-1307.21%-841.24%-
Pretax Margin
-758.23%-3.73%-243.42%-1192.47%-814.73%-
Profit Margin
-753.60%-3.73%-243.42%-1192.47%-814.73%-
FCF Margin
-654.92%24.36%-238.15%-941.72%-288.82%-

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
-40.36----
PS Ratio
75.349.8315.9826.7529.34-